Picture loading failed.

Pre-Made Caplacizumab biosimilar, Nanobody, Anti-VWF Antibody: Anti-F8VWF/VWD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-093-1mg 1mg 3090
GMP-Bios-ab-093-10mg 10mg Inquiry
GMP-Bios-ab-093-100mg 100mg Inquiry
GMP-Bios-ab-093-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Caplacizumab biosimilar, Nanobody, Anti-VWF Antibody: Anti-F8VWF/VWD therapeutic antibody
INN Name Caplacizumab
TargetVWF
FormatNanobody
DerivationHumanized
Species ReactivityHuman
CH1 Isotypena
VD LCna
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesAblynx
Conditions ApprovedThrombotic thrombocytopenic purpura
Conditions Activena
Conditions DiscontinuedThrombosis
Development TechNanobody Technology